

Kansas Bureau of Investigation

Tony Mattivi Director

Kris W. Kobach Attorney General

Before the House Health and Human Services Committee Bob Stuart, Executive Officer Kansas Bureau of Investigation January 29th, 2024

Chairman Landwehr and members of the Committee:

The Kansas Bureau of Investigation (KBI) supports HB2596 and requests this Committee approve for consideration and passage into law. The Kansas Board of Pharmacy regularly consults with KBI scientists at the Forensic Science Center (FSC) in order to ensure recommended changes to Kansas law comport with the Drug Enforcement Agency (DEA) Controlled Substance Code. This session, HB2596 is the result of that cooperative effort. The KBI believes the bill accurately reflects the changes including those in the definition of fentanyl related controlled substances.

These changes are important and necessary in order to empower state and local prosecutors to properly charge and convict those persons who manufacture and distribute deadly drugs like fentanyl in our state. The KBI deeply appreciates the work done by the Kansas Board of Pharmacy and this Committee.

####